



Welcome



Welcome to the EndoNET Summer Newsletter.

On the back of the agreed recruitment extension, we have had an excellent quarter of recruitment and over 200 patients have joined the trial. This includes our two best recruitment months in April and June. This goes some way to showing that our aim to recruit 792 patients by 30Nov2027 is feasible and has encouraged the NIHR to greenlight recruitment of EndoNET patients to **Trans-EndoNET**. Thank you all for your continuing efforts to screen and recruit patients and keep going!

36 sites are now recruiting with Ninewells and Swansea opening in May and more to follow. We are also planning to open internationally by 2026 and this is in progress.

Trans-EndoNET

The study aims to characterise the relationship between patient insulin metabolism and tumour response to endocrine therapy (ET) in early breast cancer. Protocol V5.0 will include Trans-EndoNET as a bolt-on project to the main EndoNET trial and involves taking a single fasted blood sample at the 2-4 week clinic visit. We will approach sites to take part in the near future.



EndoNET Recruitment Championship

The **quarterly winners** for recruiting 3 or more patients are Basildon (5), Glenfield (4), Rotherham (5), and Whiston (3). Treats are on their way.

In the next quarter we'll be rewarding the 5 sites that most improve recruitment between 01Jul2025 and 30Sep2025 so any sites that are yet to recruit have a good shot at winning (minimum x2 patients recruited). Keep going!

Site*	Recruited Apr-Jun 2025	Total
Churchill (Oxford)	1	28
Basildon	5	25
Southampton	2	20
Castle Hill	2	15
Whiston	3	12
Torbay	1	11
Yeovil	2	11
Royal Devon & Exeter	0	10
Southend	0	10
Rotherham	5	9
Glenfield	4	8
Nottingham City	2	8
Royal Hampshire	2	8
Cumberland Infirmary	2	6
RAEI	1	5
St Albans	0	4
Southmead	0	3
Aberdeen RI	0	2
Barnsley	0	2
Belfast City	0	2
Hairmyres	0	2
QE Birmingham	0	2
Altnagelvin	0	1
Llandough	0	1
Luton and Dunstable	0	1
Grand Total	32	206

* The 11 sites yet to recruit are not included in the recruitment table.



Investigator Meetings

We are running an **on-line Investigator Forum on 08Jul2025** focussing on approaching patients. This is aimed at newer sites and those that have struggled to recruit so far and aims to optimise your approach to recruitment ratio. If you have not received a calendar invite then please let us know.



We are also organising a face to face Investigator Meeting at the **Athenaeum Club** in London on 06Oct2025. Please add to your calendars. More information to follow.

<https://theathenaeum.co.uk/>



Associate PI Scheme

Associate PIs have contributed to EndoNET by identifying, recruiting and following up patients. The API scheme aims to develop junior doctors, nurses and allied health professionals to become the PIs of the future and provides formal recognition of a trainee's engagement in NIHR Portfolio research studies. For more information, please see the link below:

[Associate Principal Investigator Scheme | NIHR](#)

Screening Guidance

We now have screening data on over 2,500 patients. This CONSORT data is a great resource for both EndoNET and clinical trials in general but it is important that we are screening consistently to the following criteria:

- **Post-menopausal women**
- **Strongly ER+ (Allred 7 or 8)**
- **Tumour ≥ 15 mm**

If patients do not meet any of these criteria then they are unlikely to ever be eligible for the trial.

All screening data should be added directly into REDCap and kept up-to-date. This helps us to monitor progress and can indicate where you might need extra support.

If you have any screening/eligibility queries, contact endonet@nds.ox.ac.uk.



Stopping HRT

Concurrent use (at the time of randomisation) of HRT or any other oestrogen-containing medication (including vaginal oestrogens) excludes patients from joining the trial. According to our CONSORT data, **54 patients** have been recorded as ineligible due to this criteria. However, as long as the patient stops this medication when they are randomised (there is no wash out period) then they **become eligible**.